Compare MRCY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCY | ACAD |
|---|---|---|
| Founded | 1981 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | 1997 | 2000 |
| Metric | MRCY | ACAD |
|---|---|---|
| Price | $77.20 | $20.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $109.00 | $30.53 |
| AVG Volume (30 Days) | 525.3K | ★ 1.6M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.08 | ★ 69.12 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $983,622,000.00 | $726,437,000.00 |
| Revenue This Year | $10.41 | $18.71 |
| Revenue Next Year | $11.49 | $12.44 |
| P/E Ratio | ★ N/A | $103.10 |
| Revenue Growth | 7.85 | ★ 40.45 |
| 52 Week Low | $65.04 | $18.39 |
| 52 Week High | $128.45 | $30.96 |
| Indicator | MRCY | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 44.42 |
| Support Level | $72.04 | $20.10 |
| Resistance Level | $87.78 | $20.57 |
| Average True Range (ATR) | 3.38 | 0.57 |
| MACD | 0.65 | 0.37 |
| Stochastic Oscillator | 49.58 | 78.37 |
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.